Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2012-10-04 AGM Information
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Annual General Meeting and inaugural Annual Review 1
AGM Information Classification · 95% confidence The document is an ASX media announcement dated 5 October 2012 regarding Invion Limited's Annual General Meeting (AGM) scheduled for 8 November 2012. It mentions the mailing of the Notice of Annual General Meeting and Explanatory Memorandum to shareholders. It also states that Invion Limited's inaugural Annual Review is released today. The document is relatively short (2776 characters) and serves as an announcement of the AGM and the release of the Annual Review, rather than containing the full Annual Report or detailed financial statements. Therefore, it fits best as an AGM Information announcement rather than the full Annual Report or other categories. The presence of the Notice and Explanatory Memorandum being mailed supports this classification. Hence, the filing type is AGM Information (AGM-R).
2012-10-04 English
Notice of Annual General Meeting/Proxy Form 26 pages 611.0KB
AGM Information Classification · 95% confidence The document is titled 'Notice of Annual General Meeting' and includes detailed information about the upcoming AGM, such as date, time, location, agenda items including financial statements and reports, directors' remuneration report, re-election of directors, and special business resolutions. It also contains an explanatory memorandum to assist shareholders in voting. The content is typical of a notice sent to shareholders prior to an AGM, outlining what will be discussed and voted on, rather than the actual reports or minutes of the meeting. The document length is about 15,000 characters, which is consistent with a detailed notice and explanatory memorandum. There is no indication that this is the actual Annual Report (10-K) or the full financial statements, but rather a notice and supporting explanatory information for the AGM. Therefore, the document fits the category of AGM Information (AGM-R).
2012-10-04 English
Inaugural Annual Review 80 pages 2.3MB
Annual Report Classification · 95% confidence The document is titled 'ANNUAL REVIEW 2012' and contains detailed information about the company's profile, operations, pipeline, management team, and strategic outlook. It includes a letter from the Chairman and CEO addressing shareholders, discussing company progress, clinical trials, and future plans. The content is comprehensive and covers business activities, management commentary, and operational milestones for the year 2012. There are no indications that this is merely an announcement or a brief summary; rather, it appears to be a full annual report. The length (15,000 characters) supports this as well. Therefore, this document fits the definition of an Annual Report (10-K). FY 2012
2012-10-04 English
Change of Director's Interest Notice 2 pages 251.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market trade), and other related information. This matches the description of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document is specific to a director's share transactions and does not contain financial statements or broader company information, so it is not an Annual Report or Earnings Release. The document length is 3365 characters, which is consistent with a detailed director dealing notice rather than a full report. Therefore, the correct classification is Director's Dealing (DIRS).
2012-09-23 English
Change of Director's Interest Notice 2 pages 251.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities held by a director, including dates, number of shares acquired, and nature of the transaction. The content is focused on reporting personal share transactions by a company director. The document length is 3280 characters, which is typical for a director's dealing notice. There is no financial performance data, audit information, or other report content. Therefore, this document fits the definition of 'Director's Dealing' (DIRS).
2012-09-18 English
Receipt of R&D tax rebate 1 page 258.8KB
Capital/Financing Update Classification · 95% confidence The document is a media announcement from Invion Limited dated 18 September 2012. It discusses the receipt of an R&D tax rebate and the company's cash position, along with details about ongoing and planned clinical trials. There are no financial statements, detailed financial analysis, or comprehensive reporting typical of annual or interim reports. The document is relatively short (3770 characters) and serves as an update on financing related to R&D tax incentives and cash reserves. It does not present earnings results, management discussion, or regulatory filings. The content fits best as a Capital/Financing Update (CAP) since it informs about cash inflows from a tax rebate and how the funds will be used to support clinical and business plans.
2012-09-17 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.